What is Candel Therapeutics, Inc.'s revenue?

Candel Therapeutics, Inc. (CADL) generated $124.0K in revenue over the trailing twelve months.

Is Candel Therapeutics, Inc. profitable?

Candel Therapeutics, Inc. is not currently profitable: it reported a net loss of $54.4M over the trailing twelve months, a -15156.5% net margin.

What is Candel Therapeutics, Inc.'s earnings per share?

Candel Therapeutics, Inc.'s diluted EPS over the trailing twelve months is $-0.99.

Where does Candel Therapeutics, Inc.'s income statement data come from?

Every line is extracted from Candel Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Candel Therapeutics, Inc. CADL Income Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY QoQ

Simplified Detailed

	TTM Q1 '26	TTM Q4 '25	TTM Q3 '25	TTM Q2 '25	TTM Q1 '25
Research and development	$36.32M+88.9%	$30.5M+57.9%	$24.29M+11.6%	$21.24M-4.3%	$19.23M-16.9%
General and administrative	$20.1M+39.9%	$17.77M+26.4%	$16.37M+18.7%	$14.97M+11.1%	$14.37M+6.3%
Other operating expenses	$56.42M+67.9%	$48.27M+44.6%	$40.66M+14.4%	$36.21M+1.6%	$33.6M-8.3%
Total operating expenses	$56.42M+67.9%	$48.27M+44.6%	$40.66M+14.4%	$36.21M+1.6%	$33.6M-8.3%
Operating income	-$56.42M-67.9%	-$48.27M-44.6%	-$40.66M-14.4%	-$36.21M-1.6%	-$33.6M+8.3%
Interest expense	$3.38M+93.0%	$2.12M+1.4%	$1.09M-53.9%	$1.42M-44.5%	$1.75M-33.5%
Interest income	$4.3M+153%	$3.92M+260%	$3.1M+156%	$2.39M+61.5%	$1.7M+0.6%
Other income (expense), net	——	——	$17.9M—	$14.07M—	-$5.98M—
Net investment gains (losses)	$88.75K—	$89K—	——	——	——
Net income	-$54.42M-37.5%	-$38.18M+30.8%	-$22.76M+56.4%	-$22.14M+55.7%	-$39.58M-5.9%
Diluted earnings per share	-$0.99+25.6%	-$0.72+58.6%	-$0.56+67.6%	-$0.68+59.8%	-$1.33-3.9%
Basic earnings per share	-$0.99+24.4%	-$0.70+59.8%	-$0.54+68.8%	-$0.66+60.9%	-$1.31-2.3%
Weighted-average shares, diluted	221.7M+49.5%	214.1M+74.4%	192.8M+60.7%	169.9M+45.3%	148.3M+27.9%
Weighted-average shares, basic	221.7M+53.9%	209.8M+70.9%	188.5M+57.1%	165.7M+41.7%	144M+24.2%
Interest income and other, net	$4.3M+153%	$3.92M+260%	$3.1M+156%	$2.39M+61.5%	$1.7M—
EBIT	-$56.42M-67.9%	-$48.27M-44.6%	-$40.66M-14.4%	-$36.21M-1.6%	-$33.6M+8.3%
EBITDA	-$55.71M-70.3%	-$47.46M-46.1%	-$39.77M-14.8%	-$35.32M-1.6%	-$32.71M+8.4%
EBITDA	-$55.71M-70.3%	-$47.46M-46.1%	-$39.77M-14.8%	-$35.32M-1.6%	-$32.71M+8.4%
EBIT	-$56.42M-67.9%	-$48.27M-44.6%	-$40.66M-14.4%	-$36.21M-1.6%	-$33.6M+8.3%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Ask your AI about Candel Therapeutics, Inc..

Connect your AI assistant and get a quick read on the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Candel Therapeutics, Inc.'s revenue?: Candel Therapeutics, Inc. (CADL) generated $124.0K in revenue over the trailing twelve months.
Is Candel Therapeutics, Inc. profitable?: Candel Therapeutics, Inc. is not currently profitable: it reported a net loss of $54.4M over the trailing twelve months, a -15156.5% net margin.
What is Candel Therapeutics, Inc.'s earnings per share?: Candel Therapeutics, Inc.'s diluted EPS over the trailing twelve months is $-0.99.
Where does Candel Therapeutics, Inc.'s income statement data come from?: Every line is extracted from Candel Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.